Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 79

1.

Bioactivation of drugs: risk and drug design.

Walsh JS, Miwa GT.

Annu Rev Pharmacol Toxicol. 2011;51:145-67. doi: 10.1146/annurev-pharmtox-010510-100514. Review.

PMID:
21210745
2.

Bis(monoacylglycerol)phosphate as a non-invasive biomarker to monitor the onset and time-course of phospholipidosis with drug-induced toxicities.

Tengstrand EA, Miwa GT, Hsieh FY.

Expert Opin Drug Metab Toxicol. 2010 May;6(5):555-70. doi: 10.1517/17425251003601961. Review.

PMID:
20370598
3.

Elucidation of potential bortezomib response markers in mutliple myeloma patients.

Hsieh FY, Tengstrand E, Pekol TM, Guerciolini R, Miwa G.

J Pharm Biomed Anal. 2009 Jan 15;49(1):115-22. doi: 10.1016/j.jpba.2008.09.053. Epub 2008 Oct 17.

PMID:
19062221
4.
5.

Species-specific, P450- and sulfotransferase-mediated novel ring contraction of a naphthyridine-N-oxide compound in cynomolgus monkey.

Daniels JS, Espina R, Cao K, Yuan H, Lin J, Diamond S, Johnson B, Rodgers J, Prakash S, Unger S, Christ D, Miwa G, Gan LS, Mutlib A.

Chem Res Toxicol. 2007 Nov;20(11):1709-17. Epub 2007 Oct 17.

PMID:
17939741
6.

Drug safety evaluation through biomarker analysis--a toxicity study in the cynomolgus monkey using an antibody-cytotoxic conjugate against ovarian cancer.

Hsieh FY, Tengstrand E, Lee JW, Li LY, Silverman L, Riordan B, Miwa G, Milton M, Alden C, Lee F.

Toxicol Appl Pharmacol. 2007 Oct 1;224(1):12-8. Epub 2007 Jun 29.

PMID:
17681578
7.

Interactions of cyclosporin a with breast cancer resistance protein.

Xia CQ, Liu N, Miwa GT, Gan LS.

Drug Metab Dispos. 2007 Apr;35(4):576-82. Epub 2007 Jan 12.

PMID:
17220244
8.

A novel model for the prediction of drug-drug interactions in humans based on in vitro cytochrome p450 phenotypic data.

Lu C, Miwa GT, Prakash SR, Gan LS, Balani SK.

Drug Metab Dispos. 2007 Jan;35(1):79-85. Epub 2006 Oct 4.

PMID:
17020957
9.

Determination of drug plasma protein binding by solid phase microextraction.

Musteata FM, Pawliszyn J, Qian MG, Wu JT, Miwa GT.

J Pharm Sci. 2006 Aug;95(8):1712-22.

PMID:
16795010
10.

Comparison of intrinsic clearance in liver microsomes and hepatocytes from rats and humans: evaluation of free fraction and uptake in hepatocytes.

Lu C, Li P, Gallegos R, Uttamsingh V, Xia CQ, Miwa GT, Balani SK, Gan LS.

Drug Metab Dispos. 2006 Sep;34(9):1600-5. Epub 2006 Jun 21.

PMID:
16790553
11.

Comparison of species differences of P-glycoproteins in beagle dog, rhesus monkey, and human using Atpase activity assays.

Xia CQ, Xiao G, Liu N, Pimprale S, Fox L, Patten CJ, Crespi CL, Miwa G, Gan LS.

Mol Pharm. 2006 Jan-Feb;3(1):78-86.

PMID:
16686372
12.
13.

Investigation of drug-drug interaction potential of bortezomib in vivo in female Sprague-Dawley rats and in vitro in human liver microsomes.

Lu C, Gallegos R, Li P, Xia CQ, Pusalkar S, Uttamsingh V, Nix D, Miwa GT, Gan LS.

Drug Metab Dispos. 2006 Apr;34(4):702-8. Epub 2006 Jan 27.

PMID:
16443666
14.

Evaluation of microdosing to assess pharmacokinetic linearity in rats using liquid chromatography-tandem mass spectrometry.

Balani SK, Nagaraja NV, Qian MG, Costa AO, Daniels JS, Yang H, Shimoga PR, Wu JT, Gan LS, Lee FW, Miwa GT.

Drug Metab Dispos. 2006 Mar;34(3):384-8. Epub 2005 Dec 2.

PMID:
16326814
15.

Strategy of utilizing in vitro and in vivo ADME tools for lead optimization and drug candidate selection.

Balani SK, Miwa GT, Gan LS, Wu JT, Lee FW.

Curr Top Med Chem. 2005;5(11):1033-8. Review.

PMID:
16181128
16.
17.

Human metabolism of the proteasome inhibitor bortezomib: identification of circulating metabolites.

Pekol T, Daniels JS, Labutti J, Parsons I, Nix D, Baronas E, Hsieh F, Gan LS, Miwa G.

Drug Metab Dispos. 2005 Jun;33(6):771-7. Epub 2005 Mar 11.

PMID:
15764713
18.

Expression, localization, and functional characteristics of breast cancer resistance protein in Caco-2 cells.

Xia CQ, Liu N, Yang D, Miwa G, Gan LS.

Drug Metab Dispos. 2005 May;33(5):637-43. Epub 2005 Feb 16.

PMID:
15716365
19.

Testing paradigm for prediction of development-limiting barriers and human drug toxicity.

Sasseville VG, Lane JH, Kadambi VJ, Bouchard P, Lee FW, Balani SK, Miwa GT, Smith PF, Alden CL.

Chem Biol Interact. 2004 Nov 1;150(1):9-25. Review.

PMID:
15522258
20.

The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective.

Bjornsson TD, Callaghan JT, Einolf HJ, Fischer V, Gan L, Grimm S, Kao J, King SP, Miwa G, Ni L, Kumar G, McLeod J, Obach RS, Roberts S, Roe A, Shah A, Snikeris F, Sullivan JT, Tweedie D, Vega JM, Walsh J, Wrighton SA; Pharmaceutical Research and Manufacturers of America (PhRMA) Drug Metabolism/Clinical Pharmacology Technical Working Group; FDA Center for Drug Evaluation and Research (CDER).

Drug Metab Dispos. 2003 Jul;31(7):815-32.

PMID:
12814957
21.

The conduct of in vitro and in vivo drug-drug interaction studies: a PhRMA perspective.

Bjornsson TD, Callaghan JT, Einolf HJ, Fischer V, Gan L, Grimm S, Kao J, King SP, Miwa G, Ni L, Kumar G, McLeod J, Obach SR, Roberts S, Roe A, Shah A, Snikeris F, Sullivan JT, Tweedie D, Vega JM, Walsh J, Wrighton SA; Pharmaceutical Research and Manufacturers of America Drug Metabolism/Clinical Pharmacology Technical Working Groups.

J Clin Pharmacol. 2003 May;43(5):443-69. Review.

PMID:
12751267
22.

The species-dependent metabolism of efavirenz produces a nephrotoxic glutathione conjugate in rats.

Mutlib AE, Gerson RJ, Meunier PC, Haley PJ, Chen H, Gan LS, Davies MH, Gemzik B, Christ DD, Krahn DF, Markwalder JA, Seitz SP, Robertson RT, Miwa GT.

Toxicol Appl Pharmacol. 2000 Nov 15;169(1):102-13.

PMID:
11076702
23.

The life and times of anthony Y. H. Lu

Miwa GT.

Drug Metab Dispos. 1998 Dec;26(12):1174. No abstract available.

PMID:
9860922
26.

Goals, design, timing, and future opportunities for nonclinical drug metabolism studies.

Miwa GT.

Toxicol Pathol. 1995 Mar-Apr;23(2):131-5. Review.

PMID:
7569666
27.
28.

(-)-6-Aminocarbovir pharmacokinetics and relative carbovir exposure in rats.

Yeager RL, Brouwer KR, Miwa GT.

Drug Metab Dispos. 1991 Mar-Apr;19(2):462-6.

PMID:
1676655
29.

Identification of a glucuronide conjugate of the carbocyclic nucleoside, carbovir, isolated from marmoset urine.

Patanella JE, Walsh JS, Unger SE, Miwa GT, Parry PS, Daniel MJ, Evans GL.

Drug Metab Dispos. 1990 Nov-Dec;18(6):1092-5. No abstract available.

PMID:
1981518
30.

The metabolism and excretion of carbovir, a carbocyclic nucleoside, in the rat.

Walsh JS, Patanella JE, Unger SE, Brouwer KR, Miwa GT.

Drug Metab Dispos. 1990 Nov-Dec;18(6):1084-91.

PMID:
1981517
31.

The pharmacokinetics of (-)-carbovir in rats. Evidence for nonlinear elimination.

Brouwer KR, St Claire RL, Lagarde J, Patanella JE, Walsh JS, Miwa GT.

Drug Metab Dispos. 1990 Nov-Dec;18(6):1078-83.

PMID:
1981516
32.

The role of metabolism and covalent binding in the cytotoxicity of a nitrogen-containing steroid toward rat hepatocytes.

Kedderis GL, Argenbright LS, Miwa GT.

Toxicol Appl Pharmacol. 1990 Apr;103(2):222-7.

PMID:
2330586
33.

Metabolism of a nitrogen-containing steroid by rat hepatocytes and hepatic subcellular fractions.

Kedderis GL, Argenbright LS, Walsh JS, Smith JL, Stearns RA, Arison BA, Miwa GT.

Drug Metab Dispos. 1989 Nov-Dec;17(6):606-11.

PMID:
2575495
34.

Covalent interaction of 5-nitroimidazoles with DNA and protein in vitro: mechanism of reductive activation.

Kedderis GL, Argenbright LS, Miwa GT.

Chem Res Toxicol. 1989 May-Jun;2(3):146-9.

PMID:
2519718
35.

In vitro studies on the interaction of famotidine with liver microsomal cytochrome P-450.

Wang RW, Miwa GT, Argenbright LS, Lu AY.

Biochem Pharmacol. 1988 Aug 1;37(15):3049-53. No abstract available.

PMID:
2899433
36.

Studies with nitrogen-containing steroids and freshly isolated rat hepatocytes: role of cytochrome P-450 in detoxication.

Kedderis GL, Argenbright LS, Miwa GT.

Toxicol Appl Pharmacol. 1988 May;93(3):403-12.

PMID:
3368919
37.

Mechanism of reductive activation of a 5-nitroimidazole by flavoproteins: model studies with dithionite.

Kedderis GL, Argenbright LS, Miwa GT.

Arch Biochem Biophys. 1988 Apr;262(1):40-8.

PMID:
3128179
38.

The metabolic activation of nitroheterocyclic therapeutic agents.

Kedderis GL, Miwa GT.

Drug Metab Rev. 1988;19(1):33-62. Review. No abstract available.

PMID:
3293954
39.

Kinetic isotope effects and 'metabolic switching' in cytochrome P450-catalyzed reactions.

Miwa GT, Lu AY.

Bioessays. 1987 Nov;7(5):215-9. Review. No abstract available.

PMID:
3325050
40.

Structural alterations that differentially affect the mutagenic and antitrichomonal activities of 5-nitroimidazoles.

Walsh JS, Wang R, Bagan E, Wang CC, Wislocki P, Miwa GT.

J Med Chem. 1987 Jan;30(1):150-6.

PMID:
3543363
41.

Tissue drug residues and their toxicological significance.

Lu AY, Wislocki PG, Chiu SH, Miwa GT.

Drug Metab Rev. 1987;18(2-3):363-78. Review. No abstract available.

PMID:
3330522
42.

The metabolic activation of ronidazole [(1-methyl-5-nitroimidazole-2-yl)-methyl carbamate] to reactive metabolites by mammalian, cecal bacterial and T. foetus enzymes.

Miwa GT, Wang R, Alvaro R, Walsh JS, Lu AY.

Biochem Pharmacol. 1986 Jan 1;35(1):33-6. No abstract available.

PMID:
3940524
43.

Studies on the mechanism of activation and the mutagenicity of ronidazole, a 5-nitroimidazole.

Miwa GT, Wislocki P, Bagan E, Wang R, Walsh JS, Lu AY.

Adv Exp Med Biol. 1986;197:527-35.

PMID:
3766278
44.

Role of superoxide in the N-oxidation of N-(2-methyl-1-phenyl-2-propyl)hydroxylamine by the rat liver cytochrome P-450 system.

Duncan JD, Di Stefano EW, Miwa GT, Cho AK.

Biochemistry. 1985 Jul 16;24(15):4155-61.

PMID:
2996591
46.

Mechanisms of N-demethylation reactions catalyzed by cytochrome P-450 and peroxidases.

Hollenberg PF, Miwa GT, Walsh JS, Dwyer LA, Rickert DE, Kedderis GL.

Drug Metab Dispos. 1985 May-Jun;13(3):272-5. No abstract available.

PMID:
2861981
47.
48.

Drug residue formation from ronidazole, a 5-nitroimidazole. VII. Comparison of protein-bound products formed in vitro and in vivo.

Miwa GT, Alvaro RF, Walsh JS, Wang R, Lu AY.

Chem Biol Interact. 1984 Jul;50(2):189-202.

PMID:
6744464
49.

The mechanism of the cytochrome P-448 mediated 6-hydroxylation of 7-ethoxycoumarin.

Walsh JS, Miwa GT.

Biochem Biophys Res Commun. 1984 Jun 29;121(3):960-5.

PMID:
6611155

Supplemental Content

Support Center